Introduction {#Sec1}
============

Recent advancements in perinatal management have led to an increase in the survival rate of preterm infants with fetal growth restrictions, resulting in infants who are small for gestational age (SGA) at birth. Around 90% of children who are born SGA achieve normal growth by age 2^[@CR1],[@CR2]^. However, approximately 10% of children born SGA do not, leading to children with short stature^[@CR3]--[@CR5]^, which may persist through to adulthood^[@CR6],[@CR7]^. To ensure that children with severe short stature achieve their normal growth, they can be treated with growth hormone (GH)^[@CR8],[@CR9]^. Recent studies have revealed that GH treatment not only helps achieve normal growth, but also improves abnormal lipid and amino acid metabolic conditions^[@CR10]--[@CR12]^. Treatment with GH for short children born SGA has been explored for almost 40 years^[@CR13],[@CR14]^ and is currently an approved treatment in many countries^[@CR8],[@CR15],[@CR16]^. Thus, monitoring for growth and adequate introduction of GH treatment are important issues in the follow-up of children born SGA.

In terms of follow-up for infants with SGA, it is important to know the incidence and neonatal risk factors associated with short stature that needs GH treatment. We previously reported in a Japanese city population-based study that the estimated incidence of short children born SGA that met the criteria for GH treatment was 0.06% and 1.6% in all 3-year-old children and 3-year-old SGA children, respectively^[@CR17]^. However, due to the study design, early preterm infants (i.e., ≤32 weeks' GA) were not included sufficiently. The incidence of short stature increases as gestational age (GA) decreases^[@CR4],[@CR5],[@CR17]^. Early preterm infants are generally admitted to neonatal intensive care units, and some demonstrate complications due to prematurity. In early preterm SGA infants, neonatal risk factors for the development of short stature and short stature that is severe enough to warrant treatment with GH may exist; however, they have not yet been fully investigated. Thus, this study aimed to reveal the incidence and neonatal risk factors of short stature and short stature treated with GH in early preterm infants born SGA through a multiple hospital-based prospective cohort study.

Results {#Sec2}
=======

Incidence {#Sec3}
---------

During the study period in both hospitals combined, a total of 604 infants were born ≤32 weeks' GA and 76 (13%) were SGA. Two infants were excluded because of chromosomal abnormality. Finally, 74 SGA infants were enrolled in this prospective study. The incidence of short children born SGA and those treated with GH were 36% and 19%, respectively (Fig. [1](#Fig1){ref-type="fig"}). Subject selection and enrolment in each hospital are shown in Supplementary Figs [1](#MOESM1){ref-type="media"} and [2](#MOESM1){ref-type="media"}. Incidence of short stature and short stature treated with GH between the two hospitals was not significantly different (p = 0.641, p = 0.651, Table [1](#Tab1){ref-type="table"}).Figure 1Flowchart of the subject selection and enrolment process. SDS, standard deviation score; SGA, small-for-gestational age.Table 1Comparison of incidence of short stature and short stature treated with GH between the two hospitals.Nihon University Itabashi Hospital, n = 41Kobe University Hospital, n = 33p-valueShort stature at age 214 (34)13 (39)0.641GH treatment at age 37 (17)7 (21)0.651Data are shown as number (percentage). GH, growth hormone.

Associated factors for short stature {#Sec4}
------------------------------------

Univariate analyses comparing short stature and non-short stature groups revealed that birthweight (BW), birth length (BL), birth head circumference, standard deviation scores (SDSs) of BW, BL, and birth head circumference, GA, Apgar score (1 min, 5 min), duration of artificial ventilation, duration of oxygen therapy, respiratory distress syndrome (RDS), patent ductus arteriosus (PDA), chronic lung disease at 36 weeks' corrected GA (CLD36), and meconium disease were significantly different between the two groups (Table [2](#Tab2){ref-type="table"}).Table 2Factors associated with short stature.Short staturep-valueYes, n = 27No, n = 47BW, g568 (314--1174)998 (476--1426)\<0.001BW SDS−3.14 (−4.28--−1.97)−2.46 (−3.97--−1.39)\<0.001BL, cm28.5 (23.5--38.5)35.0 (26.0--39.0)\<0.001BL SDS−2.66 (−4.14--−1.45)−2.37 (−4.14--−1.30)0.020Birth head circumference, cm22.4 (13.5--27.0)26.4 (20.0--33.4)\<0.001Birth head circumference SDS−1.62 (−2.75--−0.51)−0.86 (−2.74--+0.34)\<0.001Male17 (63)22 (47)0.180GA, weeks27 (24--32)30 (26--32)\<0.001Apgar score, 1 min4 (1--8)7 (1--9)\<0.002Apgar score, 5 min7 (2--9)9 (3--10)\<0.001Use of mechanical artificial ventilation24 (89)39 (83)0.492Use of oxygen therapy27 (100)46 (98)0.445Duration of mechanical artificial ventilation, days53 (0--617)12 (0--94)\<0.001Duration of oxygen therapy, days74 (2--617)36 (3--119)\<0.001CLD3622 (82)18 (38)\<0.001Sepsis2 (7)3 (6)0.866RDS20 (74)23 (49)0.035PDA4 (15)0 (0)0.007ROP5 (19)4 (9)0.204NEC1 (4)0 (0)0.184Meconium disease8 (29.6)5 (11)0.039IVH1 (4)2 (4)0.908PVL1 (4)2 (4)0.908The values represent those for children with or without short stature. Values are shown as median (range) or number (percentage).BH, birth height; BW, birth weight; CLD36, chronic lung disease at 36 weeks' corrected GA; GA, gestational age; IVH, intraventricular haemorrhage; NEC, necrotizing enterocolitis; PDA, patent ductus arteriosus; PVL, periventricular leukomalacia; RDS, respiratory distress syndrome; ROP, retinopathy of prematurity; SDS, standard deviation score.

Associated factors for GH treatment {#Sec5}
-----------------------------------

Univariate analyses comparing GH treatment and non-GH treatment groups revealed that BW, BL, birth head circumference, SDSs of BW, BL, and birth head circumference, duration of artificial ventilation, duration of oxygen therapy, CLD36, and necrotising enterocolitis (NEC) were significantly different between the two groups (Table [3](#Tab3){ref-type="table"}).Table 3Factors associated with GH treatment.GH treatmentp-valueYes, n = 14No, n = 60BW, g588 (314--1089)925 (380--1426)0.002BW SDS−3.78 (−4.28--−2.57)−2.5 (−3.97--−1.39)\<0.001BL, cm29.7 (23.5--36.1)34.0 (25.0--39.0)0.008BL SDS−3.29 (−4.14--−2.15)−2.39 (−4.14--−1.30)\<0.001Birth head circumference, cm23.0 (13.5--27.0)26.0 (19.0--33.4)0.003Birth head circumference SDS−1.72 (−2.75--−0.75)−0.96 (−2.74--+0.34)\<0.001Male9 (64)30 (50)0.335GA, weeks28.5 (24--32)30 (24--32)0.197Apgar score, 1 min4 (1--8)7 (1--9)0.116Apgar score, 5 min7 (3--9)8 (2--10)0.058Use of mechanical artificial ventilation12 (86)51 (85)0.946Use of oxygen therapy14 (100)59 (98)0.627Duration of mechanical artificial ventilation, days49 (0--179)19 (0--617)0.035Duration of oxygen therapy, days67 (2--225)39 (3--617)0.020CLD3612 (86)28 (47)0.008Sepsis1 (7)4 (7)0.949RDS8 (57)35 (58)0.935PDA1 (7)3 (5)0.750ROP3 (21)6 (10)0.239NEC1 (7)0 (0)0.037Meconium disease4 (29)9 (15)0.230IVH1 (7)2 (3)0.515PVL0 (0)3 (5)0.393The values represent those for short children with or without GH treatment. Values are shown as median (range) or number (percentage).BH, birth height; BW, birth weight; CLD36, chronic lung disease at 36 weeks' corrected GA; GA, gestational age; GH, growth hormone; IVH, intraventricular haemorrhage; NEC, necrotising enterocolitis; PDA, patent ductus arteriosus; PVL, periventricular leukomalacia; RDS, respiratory distress syndrome; ROP, retinopathy of prematurity SDS, standard deviation score.

Multivariate analyses {#Sec6}
---------------------

Multiple logistic regression analyses using GA, BW, BL, birth head circumference, and CLD36 were performed. Only GA was identified as an independently associated factor for the development of short stature and short stature with GH treatment (odds ratio: 0.45 and 0.14, respectively, Table [4](#Tab4){ref-type="table"}).Table 4Multivariate logistic regression analyses.Short statureFactorsOR (95% CI)p-valueGA0.45 (0.20--0.97)0.042BW1.00 (0.99--1.01)0.546BL1.07 (0.65--1.77)0.791Birth head circumference2.47 (0.90--6.81)0.080CLD362.55 (0.49--13.39)0.268**GH treatmentFactorsOR (95% CI)p-value**GA0.14 (0.04--0.50)0.003BW1.00 (0.99--1.02)0.418BL1.36 (0.66--2.82)0.408Birth head circumference2.81 (0.80--9.91)0.109CLD367.44 (0.83--66.70)0.073BH, birth height; BW, birth weight; CI, confidence interval; CLD, chronic lung disease; GA, gestational age; GH, growth hormone; OR, odds ratio.

GA cut-off value for GH treatment {#Sec7}
---------------------------------

A GA cut-off value of 24 weeks was associated with GH treatment according to the Youden index based on the receiver-operating characteristic (ROC) curve analysis (Table [5](#Tab5){ref-type="table"}).Table 5GA cut-off value for GH treatment.GA, weeksSensitivitySpecificityAccuracyYouden index**240.4000.8260.7970.226**250.3750.8330.7900.208260.2860.8330.7300.119270.2000.8150.6490.015280.2590.8510.6350.110290.2780.8950.5950.173300.2080.8460.4320.054310.2070.8750.3510.082320.1891.0000.1890.189The Youden index is the point farthest from the boundary delineating the area under the curve and represents the \[sensitivity + specificity − 1\] value^[@CR31]^.GA, gestational age; GH, growth hormone.

Discussion {#Sec8}
==========

In this Japanese prospective study, we revealed that the incidences of short stature and short stature treated with GH were as high as 36% and 19% in SGA infants born at ≤32 weeks' GA, respectively. This incidence rate was high compared to that in term or late-preterm SGA infants^[@CR4],[@CR17]^. We also found that a low GA at birth was an independent risk factor for developing short stature requiring GH treatment.

Maeyama *et al*. have shown that 2.4%, 5.5%, and 6.5% of SGA infants with ≤-2.0 SDS for BW and/or BL developed short stature when born at 39--41, 37--38, and 34--36 weeks' GA, respectively^[@CR4]^. Compared with the results of Maeyama *et al*.^[@CR4]^, our study surprisingly found the incidence in SGA infants ≤32 weeks' GA to be 15--36 and 5.5 times higher in term and late-preterm infants, respectively. Thus, the incidence has GA dependency. Regarding the incidence of short stature that required GH treatment, Fujita *et al*. reported 15 (1.6%)/956 SGA infants with ≤−2.0 SDS for BW and/or BL, who qualified for GH treatment in a Japanese city population-based study^[@CR17]^. The study by Fujita *et al*. enrolled mainly term SGA infants (864 of 956, 90%)^[@CR17]^. In comparison, the incidence was 12 times higher for short stature treated with GH in SGA infants ≤32 weeks' GA.

In previous Japanese cohort studies^[@CR4],[@CR5],[@CR17]^, it was difficult to investigate clinical backgrounds because of insufficient data for preterm infants, especially extremely preterm infants. Therefore, we conducted the current multiple hospital-based prospective study to address this problem. Furthermore, as preterm SGA infants generally receive some treatments in the neonatal intensive care unit due to prematurity, we were concerned whether neonatal factors or complications influenced the development of short stature and short stature that needed GH treatment. In the univariate analysis of our current study on SGA preterm infants, GA, physical stature at birth, and CLD were factors mainly associated with developing short stature and short stature treated with GH. CLD often is associated with a high breathing work load and may affect short stature via a reduced appetite or need for extra calories for growth^[@CR18]^. Several previous studies have identified factors associated with development of short stature in SGA infants, including GA^[@CR5],[@CR17]^, BW^[@CR6]^, BL^[@CR6],[@CR19]^, and short height of parents, especially the mother^[@CR20]^. Our multivariate analyses showed that low GA is an independent risk factor. It is unclear how GA is involved in the development of short stature, but possible mechanisms include gene modifications associated with GH resistance and the intrauterine environment. There is increasing evidence that SGA children who developed short stature had a persistent abnormality in the GH/insulin-like growth factor (IGF)/insulin-like growth factor binding protein (IGFBP) axis^[@CR21]--[@CR24]^. The endocrine profile of short children born SGA is characterised by low levels of IGF-1, IGF-2, and IGFBP-3^[@CR21],[@CR25]^. These findings suggest GH resistance in short children born SGA. The correlation between short stature and epigenetic variability in the gene for IGFBP-3, resulting in the reduction of IGFBP-3 expression^[@CR26]^, has been reported^[@CR22]^. Preterm infants show altered DNA methylation in the gene encoding IGF-2^[@CR27]^. The mechanism of short stature in preterm SGA infants with a low GA may associate with IGF-related epigenetic factors.

The current study clarified that a low GA at birth was the highest risk factor for needing GH treatment among preterm SGA infants. Because puberty occurs early in preterm children with low GA^[@CR28]^, the effective period of GH treatment would be short, and accordingly, the final adult height could be short. If the GH treatment is initiated early in age, the final adult height would be achieved to the corresponding level^[@CR29]^. Therefore, it is essential to identify short stature and begin treatment as soon as possible in preterm SGA infants.

This study has some limitations. First, we could not collect the parental height of the subjects. Mid-parental heights correlated with adult height in SGA infant^[@CR19]^. However, the relationship with the height in early childhood is unknown, especially in those below age 3 years. Second, preterm SGA infants consumed a similar number of nutritional calories during the neonatal intensive care unit stay and before weaning, based on the instruction of board-certified neonatologists. However, the received nutrition levels could not be evaluated after weaning. Finally, detailed causes of fetal growth restriction that lead to SGA were not collected; however, in our subjects, causes were abnormalities in the mother, placenta, or umbilical cord, such as pregnancy-induced hypertension and placental dysfunction. Regardless of these limitations, our Japanese prospective study clearly demonstrated that 36% of 74 preterm SGA infants ≤32 weeks' GA developed short stature and 19% of those were treated with GH. Furthermore, a low GA at birth could be an early detection marker for short stature that requires GH treatment in preterm infants born SGA. Further clinical studies using a large cohort should be performed to confirm the conclusions.

Methods {#Sec9}
=======

Study design {#Sec10}
------------

A multiple hospital-based prospective cohort study for infants who were born at ≤32 weeks' GA between 2004 and 2014 and followed-up for 3 years was conducted at Kobe University Hospital, Kobe, Japan (infants were enrolled between 2004 and 2012), and Nihon University Itabashi Hospital, Tokyo, Japan (infants were enrolled between 2011 and 2015). This study was approved by the Ethics Committee of Kobe University Graduate School of Medicine (no. 160089) and Nihon University School of Medicine (no. RK-180911-24). Written informed consent was obtained from the parents of all infants. This study was carried out in accordance with the relevant guidelines and regulations.

The following neonatal data were collected: BW, BL, birth head circumference, gender, gestational age, Apgar score (1 min, 5 min), and neonatal complications such as duration of mechanical artificial ventilation, duration of oxygen administration, CLD36, sepsis, RDS, PDA, retinopathy of prematurity, mechanical artificial ventilation, oxygen administration, NEC, meconium disease, intraventricular haemorrhage, and periventricular leukomalacia. Follow-up data collected included height and body weight measured at age 2 and 3 years. Incidences of children with short stature and short stature treated with GH were determined. Neonatal risk factors were then statistically analysed.

Definition of SGA, short stature, and short stature that requires GH treatment {#Sec11}
------------------------------------------------------------------------------

SGA, short stature, and short stature that requires GH treatment were defined using the following criteria, which were based on sex-specific Japanese standards and guidelines^[@CR8]^. SGA was defined as both BW and BL \< 10th percentile and BW and/or BL \< −2.0 SDS. Short stature was defined as SGA and height SDS at age 2 years \< −2.0. Short stature with GH treatment was defined as short stature, height SDS at age 3 years \< −2.5, and height velocity SDS for 1 year \< 0.

Definitions of neonatal diseases {#Sec12}
--------------------------------

BW was measured using a digital weight scale for newborns by trained nurses. BL and birth head circumference were measured with a ruler tape. RDS was defined as requirement of artificial surfactant replacement therapy. Sepsis was determined in those with elevated serum C-reactive protein (≥0.5 mg/dl), bacterial pathogen detected from culture, and requiring antibiotic therapy. PDA was determined in those requiring indomethacin administration or surgical ligation. Retinopathy of prematurity was determined in those requiring photocoagulation therapy. NEC was determined in those requiring surgical intervention and confirmed pathological finding. Meconium disease was diagnosed in those treated with administration of a contrast agent into the digestive tract and/or surgical intervention for colostomy. Intracranial haemorrhage and periventricular leukomalacia were diagnosed by brain ultrasonography and magnetic resonance imaging. CLD was diagnosed in those who exhibited evidence of abnormalities on a chest X-ray and were dependent on oxygen therapy at 36 weeks' corrected GA.

Physical data at follow-up {#Sec13}
--------------------------

Physical data at follow-up were collected at age 2 and 3 years. Height was measured with a digital height meter and body weight was measured with a digital scale.

Calculation of SDS {#Sec14}
------------------

SDSs for BW, BL, birth head circumference, and height were calculated using nordiFIT® (Novo Nordisk Pharma, Tokyo, Japan). This can calculate SDSs for BW, BL, and birth head circumference by GA, and height during early childhood, according to sex-specific standards based on the Japanese population^[@CR5],[@CR17],[@CR30]^.

Statistical analyses {#Sec15}
--------------------

The aforementioned neonatal factors associated with short stature and short stature that required GH treatment were analysed using the Wilcoxon signed-rank test or Fisher exact test as univariate analyses, and multiple logistic regression analyses. A cut-off value for GA associated with GH treatment was determined using the maximum Youden index in the ROC curve. The Youden index is the point farthest from the boundary delineating the area under the curve and represents the \[sensitivity + specificity − 1\] value^[@CR31]^. Statistical analyses were performed using JMP version 14 (SAS Institute Inc., Tokyo, Japan). A p-value \< 0.05 was considered statistically significant.
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